Clinical trial · Observational
Pharmacogenomics of Paclitaxel in Ovarian Cancer
The Pharmacogenomics of Paclitaxel in Patients With Ovarian Cancer: Predictors of Toxicity and Response
NCT00415181CI-TRIAL-00016594completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study will try to determine whether or not certain genes are responsible for the huge variation in toxicity and effect observed between patients treated with paclitaxel (chemotherapeutic drug). Specifically we will study this in patients with ovarian cancer who receive paclitaxel/carboplatin chemotherapy after primary surgery.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Fallopian Tube Neoplasms | Fallopian Tube Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Ovarian Neoplasms | Ovarian Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Clinical diagnose and histology of invasive epithelial ovarian/tuba or peritoneal cancer * FIGO stage IIb-IV any grade or FIGO Ia-IIa only grade 3 or clear cell carcinoma (any stage and grade) * Natural candidate for paclitaxel 175mg/m2 + Carboplatin (AUC=5-6) * Baseline CA125≥70 AND/OR evaluable disease after RECIST (incl ultrasound) * 18 years or older * Caucasian (ie.parents and grandparents are Caucasian) * Performance status 2 or lower (after WHO/ECOG) Exclusion Criteria: * Prior malignant disease apart from cervical carcinoma in situ and basal cell carcinoma of the skin * Prior chemo / radiotherapy * Ongoing or imminent other chemotherapies * Pregnant or lactating * Fertile woman of childbearing potential not willing to use adequate contraception * Neurological symptoms (any kind) worse than CTCAE grade 1 * Active infection or other serious disease that could impair on treatment and/or follow-up
References
Publications (1)
- RESULTBergmann TK, Brasch-Andersen C, Green H, Mirza M, Pedersen RS, Nielsen F, Skougaard K, Wihl J, Keldsen N, Damkier P, Friberg LE, Peterson C, Vach W, Karlsson MO, Brosen K. Impact of CYP2C8*3 on paclitaxel clearance: a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer. Pharmacogenomics J. 2011 Apr;11(2):113-20. doi: 10.1038/tpj.2010.19. Epub 2010 Apr 6. PMID 20368717